Life Sciences
How to start a pharmaceutical or biotech company, and what comes after
Forming the entity takes a day. Setting up your regulatory pathway, quality systems, IP protection, and the obligations that repeat as you grow, that's the part most guides skip.
What makes a life sciences company different
Life sciences is one of the few businesses where the science can be sound and the company can still fail on everything around it. Four things set it apart:
Regulatory clearance is the gate to revenue.
You can't sell until the FDA pathway is cleared, and the pathway you choose, IND, 510(k), PMA, BLA, sets the entire product timeline.
The science is only half the risk.
Quality systems, clinical evidence, and IP are what hold up the value, and gaps in them surface at diligence rather than at launch.
Your IP is the asset investors buy.
Weak claim drafting, an inventor-assignment gap, or a freedom-to-operate surprise in a crowded area can sink a round.
You work with regulated material and, often, human or animal subjects.
Biosafety oversight, IRB approval, and animal-care review are prerequisites, not paperwork you add later.
The order the work arrives in
Every business moves through the same broad stages. What changes by industry is what each stage demands. For life sciences:
- 01
Plan the business.
What you sell, who buys it, and how you charge.
- 02
Make it official.
Entity, registrations, and business finances kept separate from your own.
- 03
Set up the money systems.
Bookkeeping and invoicing that follow documented terms.
- 04
Set up your tools and systems.
The operational systems the business runs on, chosen so they work together. For life sciences: the quality management system, GMP, GLP, and GCP controls with data integrity, expected even at small scale and required before your filings.
- 05
Protect it.
Insurance and core agreements before the exposure starts. For life sciences: a patent portfolio and freedom-to-operate (FTO) analysis, with inventor-assignment gaps closed before they surface at diligence; IP assignment from founders, employees, and contractors; and quality agreements with any CRO or CMO (contract research or manufacturing organization), which auditors and investors expect.
- 06
Get ready for customers.
Marketing and sales practices that won't need retrofitting. For life sciences: the FDA regulatory pathway that decides when your product can reach the market, chosen before it drives the timeline; and IRB (institutional review board) approval, informed consent, and ICH-GCP compliance in place before you enroll a single trial subject.
- 07
Run and grow.
Delegation and day-to-day operations on documented terms. For life sciences: a biosafety and biosecurity program for BSL-2-or-higher lab work, committee oversight, facility certification, staff training, and CDC/USDA Select Agent Program registration when you work with regulated select agents; and an IACUC (institutional animal care and use committee) program before any animal study begins.
StartBlox sequences these for your stage and industry, one step at a time, reordered as your answers change.
The risks most life sciences founders don't see coming
You can probably name two or three of these. The full list is longer, and most of it has to be in place before your product reaches a patient, an investor, or an auditor.
No FDA regulatory strategy.
The pathway you choose, IND, 510(k), PMA, BLA, sets the entire product timeline. The wrong classification, or a missed pre-submission meeting, can add years.
Starting a clinical trial without the approvals.
IRB (institutional review board) approval, informed consent, and ICH-GCP (good clinical practice) compliance are required before you enroll a single subject.
No quality management system.
GMP, GLP, and GCP controls with data integrity are expected even at small scale, and required before your filings.
A weak patent position.
Provisional filings with weak claim drafting, inventor-assignment gaps, and freedom-to-operate (FTO) surprises in crowded therapeutic areas are where life-sciences IP fails at diligence.
Export controls on materials and know-how.
Certain biological materials, equipment, and technical data fall under export rules, and sharing them with foreign nationals or shipping them abroad can require a license. Research collaborations often reach these controls before anyone expects them to.
AI tools fed proprietary research.
Discovery models and writing aids that take in experimental data or draft regulatory documents can leak trade secrets and introduce errors into filings. A written policy sets what may go into these tools and how their output is checked.
Missing IP assignments.
Anything created inside the company, by a founder, an employee, or a contractor, needs documented IP assignment. Missing assignments surface in acquisition diligence.
Patients and trial subjects
IRB approval, informed consent, and good-clinical-practice compliance protect the people in your studies before anyone enrolls.
Regulators
the FDA pathway, quality-system controls, biosafety committee oversight, and Select Agent registration are the requirements agencies check.
Investors and acquirers
the patent portfolio, freedom-to-operate analysis, inventor and IP assignments, and CRO/CMO quality agreements are what diligence digs into.
Your employees and lab staff
biosafety training and facility certification keep lab work safe, and signed IP assignments keep what they create with the business.
Each of these is scored against your answers, sequenced into your setup plan, and re-scored as your business changes.
What keeps coming back
Formation services stop at "you're registered." A life-sciences company's obligations run on repeating cycles:
Every hire: payroll set up to file on schedule, anti-harassment training on the required refresh, and safety training for employees.
Every month and quarter: sales-tax filing and remittance where you owe it, state tax filings, and the payroll year-end reconciliation.
On the calendar: state registrations and foreign-entity reports renew, professional licenses come up for renewal, insurance comes up for its annual coverage review, your domain and handles renew, and local operating permits and facilities contracts carry renewal dates that drift up silently if no one is watching.
Ongoing reviews: the PCI self-assessment where you take card payments, and safety training, logging, and postings kept current.
StartBlox treats these as recurring obligations that come back when they're due. A "What's due" view collects what's overdue and what's coming up, and completed items reset on their real schedule instead of staying checked off forever.
How this guidance is built
The sequence and risks on this page come from a library of documented, predictable founder failure patterns, refined for each supported industry, not opinion, not motivational advice. The scoring is consistent and transparent: the same answers always produce the same result, and every score traces to the answers behind it. An AI advisor explains results in plain language, but it never changes a score. StartBlox is educational: it is not legal, financial, or insurance advice, and when a step needs a licensed professional, it says so and shows qualified options side by side. Anyone can complete the diagnostic and see their full setup plan free; every plan starts with a 14-day full-capability trial, no credit card.
Frequently asked questions
See what comes after formation for your life sciences company
Answer a few guided questions, then see your full setup plan, sequenced for your stage. Free to start, no credit card.